Wells Fargo Analyst Forecasts 138% Upside for Bluebird Bio Stock
Friday, 29 March 2024, 09:20
Risky Biotech Investment
Bluebird Bio stock is predicted to rise by 138% according to Wells Fargo analyst Yanan Zhu, reaching $3 per share in the next 12 months. Despite setbacks, the company's revenue has seen a significant increase primarily driven by its gene therapies. However, the stock is considered high risk due to its volatile nature and competition in the market.
Analyst Predictions
- Zhu Forecast: Predicts 138% upside for Bluebird Bio stock to reach $3 per share.
- Investment Warning: Consider risks associated with small patient populations and strong competition faced by the company.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.